Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Arch Pharm (Weinheim) ; 356(8): e2300110, 2023 Aug.
Article in English | MEDLINE | ID: mdl-37328442

ABSTRACT

Four series of novel pyrazole derivatives (compounds 17a-m, 18a-m, 19a-g, and 20a-g) were synthesized, and their antibacterial and antifungal activities were evaluated. Most of the target compounds (17a-m, 18k-m, and 19b-g) showed strong antifungal activity and high selectivity relative to both Gram-positive and Gram-negative bacteria. Among them, compounds 17l (minimum inhibitory concentration [MIC] = 0.25 µg/mL) and 17m (MIC = 0.25 µg/mL) showed the strongest antifungal activity, being 2- and 4-fold more active than the positive controls gatifloxacin and fluconazole, respectively. In particular, compound 17l showed little cytotoxicity against human LO2 cells and did not exhibit hemolysis at ultrahigh concentrations, as did the positive control compounds gatifloxacin and fluconazole. These results indicate that these compounds are valuable for further development as antifungal agents.


Subject(s)
Anti-Bacterial Agents , Thiadiazoles , Humans , Anti-Bacterial Agents/pharmacology , Antifungal Agents/pharmacology , Gatifloxacin , Thiadiazoles/pharmacology , Fluconazole/pharmacology , Structure-Activity Relationship , Gram-Negative Bacteria , Gram-Positive Bacteria , Microbial Sensitivity Tests , Pyrazoles/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...